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ABSTRACT
There are more than 15, 000 approved prescription and over-the-counter drugs,
diagnostics, and intravenous supplementation products in the United States.1 Due to the
increased number of patients using medications it is important that dental providers are
aware of common adverse oral complications. The most commonly seen adverse oral
effects of medications are xerostomia, gingival hypertrophy, angular cheilitis, and
mucositis. The purpose of this study was to examine dental providers, “subjects”
knowledge of adverse oral effects of low-dose methotrexate, diltiazem, cyclosporine,
isotretinoin, and lisinopril.
Four of the five hypotheses tested demonstrated high P-values, therefore; they
were consistent with the null hypothesis. However, these four hypotheses yielded insight
into areas of further study.
When evaluating the number of continuing education hours that subjects
participate in annually compared to their responses on the survey, a statistically
v

significant difference was demonstrated. A P-value of 0.022 was obtained, with subjects
participating in 26+ hours of continuing education scoring an average of 0.629 higher
than those who participate in 25 or fewer hours of continuing education annually.
Data suggests that further studies are needed to evaluate where students are
instructed on adverse oral effects in an educational setting and how much time is spent on
the subject matter. Other areas of further investigation would include a study of
established dental providers and how could their attainment of knowledge improve. Most
importantly this data highlights a deficiency in information regarding adverse oral effects.
It is crucial that this topic be researched further and dental providers are educated on this
subject matter to ensure the highest quality of care to dental patients.
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CHAPTER I
INTRODUCTION
It is the responsibility of dental providers to understand the effect that medications
have on the oral cavity. Common adverse reactions seen in the oral cavity are
xerostomia, gingival hypertrophy, mucositis, angular cheilitis, and distortion of taste.
Due to an increase in the number of patients that are taking medications, it is important
that dental providers are familiar with commonly prescribed pharmaceuticals. The
purpose of this study was to compare dental providers’ knowledge of oral manifestations
with commonly prescribed medications specifically low-dose methotrexate, diltiazem,
cyclosporine, isotretinoin, and lisinopril.
Statement of the Problem
The research questions being investigated were:
1. Are subjects aware of the adverse oral effects of low-dose methotrexate,
diltiazem, cyclosporine, isotretinoin, and lisinopril?
2. Does knowledge of the adverse oral effects of the five given medication vary
between different demographic groups?
3. How does subjects’ knowledge of individual medications compare to the control
groups knowledge?
Significance of the Problem
Due to the increased use of pharmaceuticals it is important that dental
practitioners are able to identify oral effects of common medications. In 2002, a study
published in The Journal of the American Medical Association reported that 50 percent of
U.S. adults took at least one prescription medication during any given week. The
1

numbers are even higher for adults over 65 years of age.2 Six years after this publication,
it can be assumed that the number of Americans taking prescription medications is on the
rise. This is partly due to the baby boomer era, those of whom are advancing in age and
the increase in the medicine available. Of the 94% of patients taking prescription
medications, it has been shown that at least one medication may cause an oral side effect
or have an implication on dental treatment.3
An absence of scientific data on the adverse oral effects of medications exists,
making it a challenge to determine the number of patients affected by these reactions.
There is also a deficit in research regarding adverse oral effects; it is because of this that
the five named medications have been chosen for this study. Newer research studies
within the last 10 years have been conducted on the selected medications. Researchers
have described specific cases as they relate to a particular oral effect, but generalized data
is scarce. Dental and oral manifestations of drug therapy often are nonspecific and can
vary in severity and significance.4
Adverse Drug Reactions
Drug induced adverse reactions can have an impact on the oral cavity ranging
from, mild to severe. An adverse drug reaction is a noxious and unintended response to a
medication. Many medications have the potential to cause an adverse reaction in the oral
cavity.5 The clinical manifestation of adverse reactions can be immediate or can appear
several weeks after the initiation of treatment. An article published in General Dentistry
states that, many adverse reactions are mediated by the immune system.4
Researchers have proposed three theories on mediated response of the immune
system in relation to oral manifestations of pharmacological therapy. The first theory is
2

that there are IgE–mediated reactions, which occurs when the drug reacts with IgE
antibodies bound to mast cells. The second theory proposes that drug related cytotoxic
reactions are when the antibody binds to a drug attached to a cell surface. The third
theory postulates that when the circulation of antigens lasts for periods of time, this
allows for sensitization and antibody production.
In addition to these immunologic responses, non-immunologic factors are
overdose and toxicity of the drug itself.4 Non-immunologic factors include previous
adverse reactions, multiple medications, liver and renal disease, and gender. Gender may
influence pharmacokinetics, drug utilization, and susceptibility to the
presentation/detection of adverse drug reactions. Factors that may explain the higher
adverse event rate observed in female patients include pharmacodynamic factors,
hormonal influences, reporting bias, and increased use of medicine.6
Oral Effects of Medications
The most common oral effects of medications are xerostomia, oral
ulcerations/stomatitis, gingival hypertrophy, increased bleeding, angular cheilitis, and
alteration of taste. Xerostomia and mucositis can impair a patients ability maintain
normal oral function. Normal oral functions include mastication, speech, oral hygiene,
and swallowing. In addition, those patients suffering from xerostomia are at an increased
risk of developing caries. Other oral effects can be of an esthetic concern, such as
gingival hypertrophy and angular cheilitis. The occurrence of gingival
hypertrophy/enlargement can also produce areas in which the patient is unable to
maintain with regular oral hygiene, thus modifying plaque composition and contributing
to secondary inflammation of the periodontal tissues. It is important that dental
3

providers be familiar with the oral manifestations of adverse drug reactions as more
medications become available to the public.
Polypharmacy
Another consideration for dental providers is the practice of polypharmacy.
Polypharmacy is common in the elderly due to; multiple chronic medical problems,
prescribing of medications by multiple physicians, lack of coordination of care,
hospitalization or nursing home placement, severe illness, intake of over the counter
medications, vague symptoms, patient pressure to prescribe, and the use of additional
medications to manage drug induced conditions.3,7,8 Polypharmacy has a direct impact
on dental providers. It can be difficult to determine what medications are causing an
adverse oral effect when a patient presents with polypharmacy. Dental practitioners need
to be informed of the doses of medications, the time at which the medication is
administered, and any changes in the patients’ health. Accurate health histories are
necessary because the presence of disease could alter the excretion, absorption, or
metabolism of pharmaceuticals.6 The time at which the medication is administered will
allow dental providers and patients to monitor the onset of oral effects. If dental
practitioners are aware of the common culprits of oral related side effects, the patients
can be properly educated and symptoms can be treated as indicated.
Dental Providers Education
Dental providers’ education can vary greatly. Both dental and dental hygiene
programs, have a pharmacology course built into the curriculum, however; the number of
required credit hours differs between professions and the degree earned.
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Dental programs require that students take a four-credit pharmacology course.
The coursework discusses the therapeutic, mechanical, and physical mechanisms of
actions of classifications of medications. In addition to this, emphasis is given to
pharmacological agents that dentists commonly encounter or prescribe and the adverse
oral effects. Pharmacology is addressed again when students begin course work for the
administration of local anesthetic and nitrous oxide.
Dental hygiene programs have more variance in required pharmacology course
compared to dental schools, due to the fact that dental hygiene students can either obtain
an associates or bachelors degree. Associate degree programs require that students
complete two credits of pharmacology, whereas; a baccalaureate program mandates that
students complete three credit hours of pharmacology. Pharmacology courses for dental
hygiene students do not focus on writing prescriptions because it is not within the scope
of practice. Rather, courses focus on the physiological mechanisms of medications, drug
interactions, therapeutic actions, and adverse oral effects that can be detected intraorally.
Similar to dental students, pharmacology principles are then discussed when students are
instructed on local anesthesia techniques.
Operational Definitions
Cyclosporine:
A cyclic undecapeptide from an extract of soil fungi. It is a powerful
immunosuppressant with a specific action on T-lymphocytes. It is used for the
prophylaxis of graft rejection in organ and tissue transplantation.9
Diltiazem:
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A benzothiazepine derivative with vasodilatation action due to its antagonism of
the actions of the calcium ion in membrane functions.10
Isotretinoin:
A powerful drug used in the treatment of acne. Four to five months of
isotretinoin treatment usually leads to clearing of acne for one year or more after
medicine is stopped.11
Gingival hypertrophy:
Excessive growth of the gingiva either by an increase in the size of the constitute
cells or by an increase in their number.12
Lisinopril:
A drug of the angiostensin converting enzyme (ACE) inhibitor class that is
primarily used in treatment of hypertension, congestive failure, heart attacks, and
also in preventing renal and retinal complications of diabetes.13
Methotrexate:
A folic acid antagonist used as an antineoplastic agent; used to treat psoriasis and
rheumatoid arthritis.13
Mucositis:
Involving the inflammation of the lining of the mouth and digestive tract, and
frequently occurs in cancer patients after chemotherapy and radiation therapy.
Along with redness and swelling, patients typically experience a strong, burning
pain.14
Stomatitis:
Inflammation of the mucous membrane of the mouth.13
6

Xerostomia:
A dryness of the mouth from salivary gland dysfunction, often seen in patients
with Sjogren syndrome.15
Key Words
low-dose methotrexate, diltiazem, cyclosporine, isotretinoin, lisinopril, mucositis,
xerostomia, angular chelitis, gingival hypertorphy
Hypotheses
Hypothesis 1: Subjects’ knowledge regarding adverse oral effects of investigated
pharmaceuticals is greater as the educational level increases.
Ho: There is no significant statistical difference between knowledge and
educational levels.
Ha: There is significance statistical difference between knowledge and
educational levels.

Hypothesis 2: The longer length of time that subjects have practiced, the less
knowledge subjects have regarding adverse oral effects of the investigated
medications.
Ho: There is no significant statistical difference between the length of
time practicing and knowledge on adverse oral effects.
Ha: There is significant statistical difference between the length of time
practicing and knowledge on adverse oral effects.
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Hypothesis 3: Subjects that participate in at least twenty-six hours of continuing
education will have more knowledge in adverse oral effects of pharmaceuticals,
than those that participate in fewer continuing education hours.
Ho: There is no significant statistical difference between the number of
hours of continuing education and knowledge.
Ha: There is significant statistical difference between the number of hours
of continuing education and knowledge.

Hypothesis 4: Subjects will be knowledgeable regarding adverse oral effects
associated with gingival hypertrophy, therefore; answering half of the related
questions correctly.
Ho: Subjects will not answer half of the gingival hypertrophy questions
correctly.
Ha: Subjects will answer half of the gingival hypertrophy questions
correctly.

Hypothesis 5: Senior dental hygiene students at The University of New Mexico
will be knowledgeable regarding medications that induce gingival hypertrophy,
therefore; answering half of the associated questions correctly.
Ho: Senior dental hygiene students will not answer half the questions
regarding gingival hypertrophy correctly.
Ha: Senior dental hygiene students will answer the half questions
regarding gingival hypertrophy correctly.
8

Assumptions
An element that was beyond control during this study design was the occurrence
of inaccurate contact information of potential subjects. The assumption of this study
design was that New Mexico Board of Dental Health Care had the correct/current
addresses for the subjects. It was also assumed that all participants surveyed were all
currently residing in New Mexico. However; the potential that subjects may have moved
from New Mexico but, maintained a current dental or dental hygiene license existed and
therefore should be considered when interpreting the datum. Additionally, in preparing
this survey, it was assumed that subjects had prior knowledge of the previously
mentioned pharmaceuticals.
Limitations
Limitations of this investigation included the following: 1) subjects mistaking the
survey for unsolicited mail; 2) the response rate could have been delayed due to the
postal system or time it took to complete the paper survey; 3) this investigation only
examined subjects who are licensed in the state of New Mexico, which places
geographical limitations on the study; 4) the subjects’ ability to maintain an active license
in multiple states presents the probability that a small number of states outside of New
Mexico may have been represented during this study. Consequently, this study utilized
an anonymous survey and therefore, additional states could not be identified and; 5)
because New Mexico was the only state examined during this investigation, a limited
number of educational institutions were represented in this study.
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CHAPTER II
LITERATURE REVIEW
As the number of individuals taking prescription medication increases, so does the
risk of oral adverse drug reactions. These oral manifestations affect the oral mucous
membrane, saliva production, and taste. In an article titled, “Oral Adverse Drug
Reactions to Cardiovascular Drugs” it states, the pathogenesis of oral adverse reactions
related to the intake of medications is not well understood, and the prevalence is not
known.6 Due to the lack of research on oral manifestations of adverse drug reactions,
dental providers tend to overlook the subtle indications. It is dental practitioners’
responsibility to collect accurate health histories and to be aware of commonly prescribed
medications and their adverse oral effects. As the majority of the population continues to
age and depend on pharmaceuticals, studies will continue to emerge on adverse oral
effects.
Methotrexate
Methotrexate is commonly used in the treatment of chronic diseases such as
rheumatoid arthritis and psoriasis.16 Much research has been done on the systemic effects
of methotrexate. Comparatively, little has been done on the oral effects. Dental
practitioners should be aware of the possible oral effects of low-dose methotrexate that
have so far been largely unrecognized.17
Methotrexate is classified as an antimetabolite drug.18 It is an inhibitor of
dihydrofolate reductase, an enzyme that reduces folate to an active form where it acts as a
co-factor for the production of nucleic acids essential to DNA synthesis. The effect on
reducing DNA formation and cell turn over provides both therapeutic properties and
10

adverse side effects of the medication. Methotrexate traditionally had been used in
higher doses in the oncology setting. In the 1970’s the FDA approved low doses of
methotrexate to be effective in the treatment of rheumatoid arthritis and psoriasis.19 The
primary function of methotrexate when used to control psoriasis is to slow the growth of
skin cells; in rheumatoid arthritis methotrexate decreases the immune systems’ activity.18
Methotrexate can be used either orally or intravenously. In the 1960’s the daily
oral schedule for methotrexate was found to lead to frequent toxicity and was replaced by
a weekly oral dose schedule in the 1970’s.20 Oral administration of methotrexate varies
between 15-25mg per week. Should a patient’s need exceed 17.5mg per week, the
medication is delivered intravenously.21 Standard practice is to prescribe the lowest most
effective dose of methotrexate. If a patient requires regular low doses of methotrexate to
remain symptom free, the drug is approved for long-term usage.22
It is important that patients inform dental providers that they are undergoing lowdose methotrexate therapy. A study published in the British Medical Journal indicated
that nitrous oxide, NSAID’s, and penicillin increased low-dose methotrexate patients’
risk of developing bone marrow suppression.23 It can be difficult to remember all the
medications that one is taking. It is important to encourage patients to keep an updated
list of medications with them, as to keep their medical history current.
Side Effects of Methotrexate
Although methotrexate as been regarded as a safe and effective therapy in which
to treat chronic illnesses, it potentially can be toxic other areas of the body. The FDA has
guidelines in place to minimize patients’ risk of toxicity. Methotrexate is metabolized
through the liver, which can lead to hepatoxicity. Hepatoxicity can result from long-term
11

use of methotrexate.22 A patient taking methotrexate is at a higher risk of developing
liver cirrhosis if they have the following risk factors: abnormal kidney function, diabetes,
prior liver disease, and/or alcohol consumption.21
There are other adverse effects of methotrexate that are less severe and more
manageable than liver cirrhosis. These side effects can be seen within 24 hours of taking
the medication or throughout the entire treatment. Some of these include: nausea,
tiredness, lightheadedness, difficulty sleeping, vomiting, mouth ulcerations, easy bruising
or bleeding, fever, or chills. Studies have shown that folic acid supplementation lessens
the toxicity and side effects of methotrexate in patients.24 In a 6-month, double blind,
placebo-controlled trial, 7mg of folic acid weekly decreased methotrexate toxicity
without affecting the efficacy.24 Yet, the specific effects of folic acid on methotrexate
toxicity are still unclear. Much controversy still remains on the appropriate use in
combating the side effects of methotrexate.
Low-dose Methotrexate and Mucositis
According to an article published in General Dentistry, erythemas, edema,
mucosal shedding, ulceration, and pseudo membrane formation characterize oral
mucositis.25 Discussion of mucositis is needed to understand the oral complications
dental professionals encounter when providing care for a patient under going low-dose
methotrexate therapy.
There are multiple factors that apply when evaluating the frequency and severity
of mucositis: diagnosis, age, level of oral health, and type, dose, and frequency of drug
administrations.26 The patient’s risk of developing mucositis increases with exposure
time, dosage, and number of previous episodes of mucositis. However, oral
12

chemotherapeutic agents that interfere with DNA synthesis such as methotrexate have a
higher incidence rate of mucositis.
As discussed earlier, DNA replication and the rapid rate of mucosal cell
proliferation make the oral mucosa susceptible to mucositis. Much of the research on
mucositis is based strictly on observation. Although there are theories and suggestions as
to the precise cause of the breakdown of the mucosa, the exact process has not been
identified. According to Napenas, et al., mucositis is recognized to result from changes
both at the epithelial and subepithelial layers, with evidence of damage to
microvasculature (endothelium) and connective tissue that precedes epithelial changes in
irradiated oral mucosa.25 It has been hypothesized that mucositis is a four-phased
biologic process: initial, epithelial, ulcerative, and the healing phase.26 The majority of
available research has been directed at evaluating the epithelial phase of mucositis.
Studies have shown that antimetabolites are most toxic to the mucosa because they target
the DNA synthesis process. 27 It is during the ulcerative phase that patients are prone to
infection in which mucositis causes oral complications for the patient. The healing time
for mucositis is typically 12-16 days, but depends on the proliferation rate of the mucosa,
the reestablishment of the local flora in the oral cavity, and other extraneous factors.28
These extraneous factors include, but are not limited to, poor oral hygiene, periodontal
disease, caries, xerostomia, and nutrient deficiencies. It is important to be able to identify
the signs and symptoms of mucositis. The earliest signs and symptoms include: erythema
and edema, a burning sensation, and an increased sensitivity to hot or spicy food. The
areas of erythema can develop into raised white desquamative patches that become
painful ulcerations.28 Mucositis also compromises the body’s defenses against the
13

invasions of microorganisms from the oral cavity into the bloodstream thus, increasing
the risk of systemic infection.25 This situation can potentially lead to a cascade of events
altering the patients overall health. Painful ulcerations in the oral cavity render patients
with the inability to eat, drink, or swallow. The areas of the oral cavity that are
commonly affected by mucotoxicity are those cells that replicate quickly. In the oral
cavity, these are the non-keratinized areas such as: soft palate, cheeks, lips, ventral
surface of the tongue, and the floor of the mouth.28 The remaining areas of the oral
cavity are at a reduced risk for mucositis because of a slower cellular rate.
Treatment of Mucositis
Much research has been conducted on possible treatment options for mucositis,
however little has proved to eliminate the problem. Studies have indicated treatments
provide patients with relief, decrease the severity, or aid in decreasing the risk of
developing mucositis. Aside from adequate oral hygiene and frequent visits to the dental
provider; folic acid is the most frequently recommended preventative measure for
mucositis. A study published by the Annals Internal Medicine reports that, a controlled
trial shows that folic acid supplementation of 5mg or 27.5mg per week decreases
methotrexate toxicity without compromising efficacy.24 Aside from folic acid, other
studies have been conducted on the efficacy of chlorhexadine, hydrogen peroxide,
cryotherapy, and a variety of natural herbals in the treatment of mucositis. As researchers
discover more information on mucositis, there should be a definitive treatment of choice.
Diltiazem
In a study conducted in 1998, three percent of patients seen in an adverse drug
reaction clinic were using cardiovascular drug therapy.6 The use of calcium channel
14

blockers emerged in the 1980’s. Calcium channel blockers are used in the treatment of
cardiovascular disorders including, angina, hypertension, supraventricular arrhythmias,
and some forms of myocardial infarction.28
Diltiazem, a calcium channel blocker and vasodialator, is commonly used to treat
hypertension and angina.29 Diltiazem, a benzothiazepine, is a calcium antagonist,
inhibiting calcium ion entry into smooth muscle cells by a blockade of slow calcium
channels.30 Diltiazem is metabolized through the liver, excreted by the kidneys and the
bile. After oral administrations, diltiazem is detectable in the plasma 30-60 minutes after
oral administration. When patients are treated for angina, diltiazem assists in reducing
the heart rate and blood pressure via dialation of the coronary arteries. Diltiazem works
similarly in the treatment of hypertension. Because diltiazem is a vasodilator, blood
pressure is reduced; by suppressing the sinoatrial node stimulation.30
Side Effects of Diltiazem
Common adverse effects include, gastrointestinal discomfort, swelling,
headaches, dizziness, taste aversions, gingival hypertrophy, rash, and fatigue. Diltiazem
has shown to have adverse drug interactions with other medications. Co administration
of diltiazem with other agents, which follow the same route of biotransformation, may
result in the competitive inhibition of metabolism. It is recommended that patients that
have been prescribed diltiazem avoid or use extreme caution when taking concomitantly
beta blockers, cimetidine, digitalis, and cyslosprine.31 For this reason, it is vital that
patients provide accurate health histories to healthcare providers.
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Diltiazem Induced Taste Aversion
It is estimated that the effects of medication on the olfactory system is greatly
underestimated.32 A large number of medications in physician’s desk references make
note of possible drug interaction with the olfactory senses. According to a study
publication in the Journal of the European Academy of Dermatology and Venereology,
drugs may cause a loss of taste acuity (hypogeusia), distortion in perception of the correct
taste of a substance (dysgeusia) or loss of taste sense (ageusia).5 These effects on the
olfactory system cause food to have a bitter, salty, sour, bland, or metallic taste.
Researchers have established two mechanisms of action as the etiology of taste
disorders. The first mechanism is the excretion of the drug or its metabolites into the
salvia thus interfering with the chemical composition or flow of saliva. The second, is
the taste receptor is affected, causing a disturbance in taste.4 Few studies have been
conducted on the effect of medication on the olfactory system because multiple factors
have an influence on one’s sense of taste. Some explanations include; polypharmacy,
orally administered medications that taste bad, secondary effects from other medication,
genetics, age, and weight.32
Many calcium channel blockers have been reported to alter ones sense of taste,
specifically; ditliazem. When a patient experiences a disturbance in taste, symptoms
typically dissipate within two to three months after the initiation of the pharmaceutical
treatment. If an individual not experiences an alteration in taste, but also xerostomia, this
will prolong and complicate the recovery of the olfactory system.32

16

Treatment of an Altered Olfactory System
Due to the limited amount of information on the adverse effects diltiazem on the
olfactory system, treatment options are limited. As stated earlier, symptoms usually
spontaneously resolve two to three months without any medical intervention. For those
patients who do not have a spontaneous recovery, an oral examination and appropriate
patient education is vital. Routine dental examinations, proper oral hygiene, and close
nutritional balance are fundamental for the maintenance of good taste and smell health.32
If in addition to altered taste, a patient is experiencing xerostomia it is necessary to
provide patients with a saliva substitute. Chlorhexadine is a treatment option for those
patients who report a salty or bitter taste. It should be noted that, the effectiveness of
chlorhexadine might be secondary to its strong positive charge, however; there is a lack
of clinical data.32 In any case, it is important to be both sympathetic and informative to
the patient. Patients who have careers that are reliant on their sense of taste or smell
should be informed of the potential side effects of diltiazem. It is the responsibility of
healthcare providers to provide this information to patients taking diltiazem.
Diltiazem and Gingival Hypertrophy
Another common adverse oral effect of diltiazem is gingival hypertrophy.
Gingival hypertrophy is a fibrotic enlargement of the gingiva that can be induced by
various pharmacologic agents through poorly understood mechanisms. In 2002, The
Journal of Clinical Hypertension reported that, the prevalence of gingival overgrowth
with the use of calcium antagonists could be as high as 38%. The study reports it is also
3.3 times more likely to occur in males than females.33 Calcium channel blockers are one
of three classifications of medications that have demonstrated drug-induced gingival
17

overgrowth. In study conducted by Prisant Herman it was concluded that significant
gingival overgrowth occurs in 2.2% of patients on diltiazem therapy.33
As stated, the mechanisms by which calcium channel blockers adversely impact
the gingiva are poorly understood. Most theories focus on the effect that the drug has on
the gingival fibroblast. Not every patient undergoing diltiazem therapy is affected by
gingival hypertrophy. It is likely that a variety of factors are responsible such as: genetic
predisposition, pharmacokinetic variables, and inflammatory factors.33 In addition to the
above-mentioned risk factors: age, sex, periodontal status, and the presence of plaque
also contribute to gingival overgrowth.
It is important that patients who have undergone diltiazem therapy have an
understanding of the need for good plaque control. Although researchers do not
understand how calcium channel blockers affect the gingiva, they do recognize that poor
oral health contributes and can exasperate gingival hypertrophy. Preventing gingival
inflammation in patients using calcium channel blockers may help control the degree of
drug-induced gingival enlargment.34 Gingival hypertrophy can range from mild to
severe. Gingival hypertrophy primarily affects the interdental papilla and labial
gingiva.13 This usually begins as a diffuse swelling of the interdental papilla; which
enlarge and coalesce, leaving a nodular appearance.28 A study published in the Journal
of Clinical Periodontology suggests that gingival inflammation has a stronger effect than
the drug treatment itself in patients treated with diltiazem. Researchers arrived at this
conclusion because of the increased prevalence in gingival inflammation, poor plaque
control, and probing depth.35 The responsibility of educating the patients on this adverse
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oral effect rests on dental providers. Dental practitioners must provide patients with both
the knowledge and tools to maintain optimum oral health.
Treatment of Gingival Hypertrophy
Gingival hypertrophy is typically visible one to three months after initiation of
medicaments. When gingival overgrowth occurs it ranges from mild to severe. Unlike
other adverse drug reactions, gingival hypertrophy does not resolve after the medication
has been discontinued. Severe gingival overgrowth can obstruct the dentition completely,
thus leaving patients incapable of maintaining good oral hygiene. Such changes are
unsightly and may result in pain, difficulty eating, and an undesirable breath odor.34
Gingival overgrowth can cause both physical and emotional pain. For patients affected
by severe gingival hypertrophy, the only treatment option is surgical intervention.
There is a 34% reoccurrence rate for drug-induced gingival hypertrophy.36 For
many years, the standard of care was performing a scalpel gingivectomy to reduce
gingival overgrowth. Recent studies have emerged comparing the results and
postoperative discomfort of scalpel and laser gingivectomies. In a study published in the
Journal of Clinical Periodontology, researchers compared post-operative pain and
recurrence rates after having scalpel and laser gingivectomies. Results yielded that
gingival overgrowth reoccurrence was significantly greater in patients who had a scalpel
gingivectomy when compared with the laser gingivectomy.36 Initial results suggest that
new “gold standard” for gingivectomies is to complete the procedure with a laser
technique. This technique does present its own disadvantages. The first disadvantage is
the cost, the second being post operative discomfort for patients. Aside from surgical
interventions, chlorhexadine mouth rinse has been reported to reverse recurrent gingival
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overgrowth following gingivectomies. A study in mice indicated it may have a role in
limiting but not preventing gingival overgrowth.27,37,38
It is important for dental providers to educate patients on the risk of gingival
hypertrophy. Because researchers can only theorize on what causes gingival overgrowth,
patients should be aware of the correlation between poor oral hygiene and drug-induced
gingival overgrowth. Patients may need to be put on more frequent recalls to allow the
gingival tissues to be monitored closely.
Cyclosporine
In the 1900’s physicians began performing organ transplants. Cyclosporine is an
immunosuppressant drug that prevents or interferes with the host’s immunologic
response to the foreign protein substances from the organ donor. Pharmacological
therapy is of fundamental importance in situations where correct and prompt
administration can improve the quality of life and survival as witnessed in transplant
recipients.39
Cyclosporine is commonly known to be used in the conjunction with organ
transplants involving skin, heart, kidney, pancreas, bone marrow, small intestine, and
lungs.40 Cyclosporine can be used to treat rheumatoid arthritis, psoriasis, and
inflammatory bowel disease. Cyclosporine is absorbed through the gastrointestinal
system. Bioavailability and peak serum concentration levels vary from patient to
patient.27 An initial dose 15mg of cyclosporine should be administered 4 to 12 hours prior
to transplantation. The dose is then decreased 5% per week until a maintenance dose of
5-10mg/kg/day is reached.40 The exact mechanism of action of cyclosporine is not
known. Experimental evidence suggests that the effectiveness of cyclosporine is due to
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specific and reversible inhibition of immunocompetent lymphocytes.40 It is
recommended that patients taking cyclosporine have routine blood work completed to
monitor plasma levels and both liver and kidney function.
Side Effects of Cyclosporine
As with all medications, cyclosporine has adverse side effects and drug
interactions. Hypertension is a common adverse effect of cyclosporine therapy,
therefore, increasing the patients’ risk of developing gingival overgrowth. Transplant
recipients are prescribed many medications to suppress the immune system but to combat
adverse side effects due to polypharmacy. Patients should avoid specific classifications
of drugs particularly, NSAIDs, antineoplastic, gastrointestinal agents, calcium channel
blockers, specific antibiotics, antifungals, and anticonvulsants.40 Because of the use of
polypharmacy with transplant patients, it is crucial that patients and providers are aware
of these common adverse effects and drug interactions. If medication is to be coadministered with cyclosporine, an in-depth review of contraindications is required.
Cyclosporine Induced Gingival Hypertrophy
Like diltiazem and other calcium channel blockers, gingival hypertrophy is a
frequent oral complication of cyclosporine. Ten to thirty percent of patients on
cyclosporine therapy experience gingival overgrowth.41 According to a study published
in, Progress in Transplantation, the dose and plasma level were significant risk factors
for the development and extent of gingival hypertrophy.42 Similar to diltiazem, gingival
hypertrophy is typically seen around the dental papilla. Cyclosporin-induced gingival
overgrowth is usually seen in the anterior segments of the mouth and on facial surfaces of
the teeth. Overgrowth is usually confined to the attached gingiva but may extend
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coronally and interfere with the occlusion, mastication, and speech without altering the
periodontium.27 As with diltiazem, gingival hypertrophy ranges from mild to severe; in
severe case two-thirds or more of the tooth structure can be obstructed.
One study evaluated the risk of gingival hypertrophy when cyclosporine was
taking in a solution versus a capsule. The effects of both preparations on the gingival
tissue demonstrated that gingival overgrowth was observed in 37% of the patients taking
the cyclosporine solution, compared to 43% dosed with capsules.43 As previously stated,
the pathogenesis of gingival overgrowth is still unknown. Researchers have hypothesized
that cyclosporine-induced gingival hypertrophy is due to the indirect and direct effects of
cyclosporine on fibroblasts and the extra cellular components of the lamina propria.27
Treatment of Cyclosporine-Induced Gingival Hypertrophy
Treatment of cyclosporine-induced gingival hypertrophy would be the same as it
is for diltiazem. The treatment options for patients experiencing drug-induced gingival
overgrowth are limited. Early studies have shown that chlorhexadine is an effective
treatment modality for plaque control, thus aiding in the prevention of gingival
hypertrophy. Drug intervention has shown to be successful in the regression of gingival
hypertrophy. Two medications in particular have been the focus of such studies,
metronidazole and azithromycin.42 The mechanism in which gingival overgrowth
responds to azithromyacin is unclear, however; researchers found that there is a reduction
in anaerobic bacteria and spirochetes.42 Surgical intervention is an option that is utilized
in cases where esthetic appearance is the concern, but patients can experience postoperative discomfort, bleeding, and reoccurrence.
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As with diltiazem, educating the patient about the adverse oral side effects is a
key component to dental treatment. More frequent dental visits can be recommended,
however; an intensive course of plaque control and removal of gingival irritants have
shown to have little effect on the development of gingival overgrowth.27 Although
studies have suggested that meticulous plaque control may not prevent gingival
overgrowth, patients are encouraged to maintain optimal health as to not exasperate the
overgrowth. Optimal oral health is important when minimizing adverse oral effects, but
it is also a key component to maintaining the patients’ overall health.
Isotretinoin
The Food and Drug Administration (FDA) approved isotretinoin, which is in the
retinoid family, in 1982. Isotretinoin or Accutane is the most frequently prescribed
medication in the treatment of moderate to severe nodulocystic acne. Acne is a
multifaceted dermatological disorder of the sebaceous glands, affecting 90-100% of
adolescents with varying degrees of severity.44 In Dermatology Nursing it states that, the
number of prescriptions for acne have increased 2.5-fold in the United States between
1992 and 2000.45,46 The side effects of isotretinoin can range from mild to life altering,
but isotretinoin is the most effective pharmaceutical agent used for managing
nodulocystic acne or treatment-resistant acne.47 Clinical improvement in nodular acne
patients occurs in association with a reduction in sebum secretion. The decrease in
sebum secretion is temporary and is related to the does and duration of treatment with
Accutane, and reflects a reduction in sebaceous gland size and an inhibition of sebaceous
gland differentiation. Nodulocystic acne is the most severe type of acne; it has the
potential to produce lifelong disfiguring scares.44 When this type of scarring occurs the
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effects can be devastating leading to embarrassment, anxiety, poor self- esteem, and
depression.
Isotretinoin is widely accepted as the treatment of choice because it is the only
acne medication that impacts all four major pathophysiologic factors of acne. However,
this is also the most potent drug. Isotretinoin significantly decreases the dimensions and
sebum production of the sebaceous glands, reverses the effect of androgens on these
structures, thus changing keratinocyte maturation and adhesion, and represses the
inflammatory component of acne and comedone production.45,48,49 Studies have been
conducted as to the efficacy of conventional and intermediate dosages of istotretinoin.
Recommended dosage by the FDA is 0.5-2.0mg/kg, this is dosage is considered to
be conventional dosaging. Intermediate or long-term dosaging of isotretinoin is when the
recommended cumulative dosage is taken over a period of time, totaling 120-150
mg/kg.50 In prescribing intermediate dosaging, studies have shown that it is effective in
minimizing adverse drug reactions and in treating treatment-resistant acne. In a study
conducted in Turkey, researchers investigated the response of acne when treated with
both intermittent and conventional isotertinoin therapy. Results yielded that intermittent
isotretinoin therapy successfully treated mild to moderate acne and that there was a
significant reduction in adverse effects.51
Side effects of isotretinoin
Patients taking isotretinoin are at risk of developing adverse drug reactions.
These reactions can affect various systems in the body including: the mucocutaneous,
ophthalmologic, teratogenicity, neuromuscular, and the gastrointestinal system.
Teratogenicity is the most potent of the adverse reactions, for this reason, the use of
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isotretinoin may be limited, either by the patients’ choice or the prescribing physician.
All patients taking istotretinoin will experience at least one side effect. As with any
medication it is important that medical providers clearly and concisely explain these risks
to the patient. Mucocutaneous effects are the most common adverse reactions of
isotretinoin; these are tolerable, treatable, and the mildest. Patients typically present with
mucosal dryness, of the nasal and oral cavity, eyes, and skin. Two thirds of patients
undergoing isotretinoin therapy report nosebleeds due to mucosal dryness and 100% of
patients experience cheilitis.49 It is vital that women who are pregnant or plan on
becoming pregnant inform their medical provider. Approximately one-fourth of all
exposed fetuses have birth defects when iostretinoin is used in conjunction with
pregnancy.49 Once treatment has been completed there are no long-term effects on
fertility. It is important to remember that the severity and frequency of adverse effects of
isotretinoin is dose dependant.
Isotretinoin and Cheilitis
Angular cheilitis is the most frequently witnessed oral complication of
isotretinoin. For this reason, it is important that dental providers are able to identify and
educate patients on this common side effect. Angular cheilitis is an inflammatory
condition that occurs in one or both angles of the mouth. This condition typically
presents with erythema, painful cracking, scaling, bleeding, and ulceration at the corners
of the mouth.52 Previous studies have shown that 100% of all patients taking isotretinoin
experience cheilitis; if a patient does not exhibit this side effect the patient is noncompliant.
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The etiology of angular cheilitis is very broad and at times can be difficult to
identify the causative agent. This mucosal condition can be indicative of an idiopathic
cause, various nutritional deficiencies, allergic reactions, fungal infections, and trauma.
Because cheilitis can be caused by a multitude of factors, the treatments vary greatly.
Due to an inconsistency in the etiology of cheilitis, dental practitioners need to
gather accurate information. All changes in a patients’ health history should be updated
to include new diagnoses and medication, including dosages. Dental providers should
investigate how long the lesions have been present, periodicity, previous treatment, and
the reoccurrence rate. It is also pertinent to evaluate the patients’ daily nutrition.
Nutritional deficiencies especially of iron and B vitamins are important in the
development of angular cheilitis. After collecting the appropriate information from
patients the severity of angular cheilitis is classified into three categories; type I (mild),
type II (moderate), and type III (severe).52
Treatment of angular cheilitis
The treatment of angular cheilitis is dependent on the etiology. For drug-induced
cheilitis, many times a lubricant is the only recommendation. Studies have shown by
simply applying a moisturizer or petroleum jelly to the cracks, this provides patients with
relief. If symptoms persist or worsen then a topical medication can be applied to the area.
Four percent of patients with cheilitis did not respond to topical moisturizers and required
topical corticosteroids.45,53 In another study that was published in the Journal of the
American Academy of Dermatology, researchers investigated that effect of Vitamin E
supplementation on angular cheilitis. Results did not fully reveal the efficacy of Vitamin
E on isotretinoin-induced cheilitis; more studies will be needed in the future to determine
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the benefits.54 Because this type of angular cheilitis is pharmacologically induced, it is
not considered to be a contagious lesion. Patients should be encouraged to maintain a
healthy oral cavity in order to reduce the risk of reoccurrence. If dental providers are
unable to obtain an accurate health history or inaccurate information as to the origin of
the lesion, angular cheilitis should be treated as an infectious lesion.
Lisinopril
It is predicted that by the year 2025 the number of adults with hypertension is to
exceed 1.5 billion worldwide.55,56 Lisinopril was approved in the 1990’s and is
commonly used in the treatment of hypertension, heart attacks, and congestive heart
failure. This medication is routinely seen in dental practices for the control of
hypertension. As the population continues to age the number of patients on
antihypertensive therapy will continue to rise.
Lisinopril is an angiotension-converting enzyme (ACE). Unlike other ACE
inhibitors, lisinopril has notable properties. It is hydrophilic, it has a long half-life and
tissue penetration, and the liver does not metabolize it.57 Unlike the majority of
pharmaceuticals, lisinopril is not metabolized but is excreted unchanged through the
urine. The usual dosage is once a day because of the long half-life of lisinopril, which is
typically an accumulation of 12 hours. A single daily dose allows for an improvement in
patient compliance. Studies in the United States and Europe have concluded that around
25% of all hypertensives and 50% of all treated patients have controlled blood pressure.55
The typical dosage is 2.5 mg for sensitive patients to 40mg. It is recommended that
lower dosages be used in patients with higher-grade renal impairment. Dosages up to 80
mg per day have been used in patients that are more tolerant of the medication.57
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To lower blood pressure, many effective treatment regimes are available and a
lower blood pressure has been shown to be associated with a decrease in cardiovascular
risk.58 The FDA reports that, two dose-response studies utilizing a once daily regimen
were conducted in 438 mild to moderate hypertensive patients that were not on a diuretic.
Blood pressure was measured 24 hours after dosing. An antihypertensive effect of
lisinopril was seen with 5mg in some patients. However, in both studies blood pressure
reduction occurred sooner and was greater in patients treated with 10, 20, or 80 mg of
lisinopril.59 Pharmacological therapy is important for patients with hypertension, but
nonpharmacological treatments can also aide in the reduction of ones’ blood pressure.
Nonpharmacological interventions include; smoking cessation, dietary changes, weight
control, decrease in sodium and alcohol consumption, and daily exercise.
Side Effects of Lisinopril
As with any medication, lisinopril is known to have common adverse reactions.
The most frequent side effects include cough, diarrhea, loss of taste, nausea, xerostomia,
drowsiness, and headaches.57 Generally, many of the side effects patients report when
taking lisinopril are both mild and transient. In clinical trials, patients with hypertension
treated with lisinopril, discontinued therapy due to clinical adverse experiences in 5.7%
of the patients. The overall frequency of adverse experiences could not be related to total
daily dosage within the recommended therapeutic dosage range.54 Dental practitioners
are concerned with the loss of taste and xerostomia due to its adverse effect on the oral
cavity.
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Lisinopril and Xerostomia
Hyposalivation (xerostomia) is defined as unstimulated whole saliva rates of 0.1
mL/min and stimulated rates of 0.7 mL/min.1 Saliva contain 99% water and 1% proteins,
enzymes, and electrolytes.60 Patients may or may not be aware of a decrease in salivation;
it is only after xerostomia begins to interfere with daily functions that one notes a change.
Xerostomia can occur as a result of medications’ effect on the sympathetic and
parasympathetic nervous system. According to an article in Compendium, other druginduced causes of xerostomia may be the result of a reduction of blood volume (diuretics)
and antihypertensiveagents.1 Although this research will focus on the adverse oral effects
of pharmaceuticals, it should be noted that systemic diseases have a direct impact on
salivary flow. When dental practitioners investigate the etiology of xerostomia, providers
need to review the medications patients take but also any systemic disease processes. As
with any adverse oral effect, xerostomia can be overlooked if the appropriate questions
and information is not gathered. Xerostomia can have a negative impact on patients’
nutritional intake and quality of life, but typically is not distinguished until there has been
a 50% reduction in salivary flow.
Patients who have xerostomia are at an increased risk of developing caries and
oral infections. It is typical that as saliva production decreases so does patients’ oral
hygiene. With an increase in plaque, acid, and bacteria those with xerostomia are at
increases risk of developing candida albicans. This infection presents with erythema and
atrophy of tongue, or a white, cheesy substance that may bleed when removed.60 The
oral tissue is at an elevate risk of tearing when gauze, instruments, and saliva ejectors are
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placed in the mouth. Dental practitioners should use caution when working in the oral
cavity of a patient with xerostomia.
Treatment of Xerostomia
Xerostomia is a condition that has no cures, but there are options available to
patients to help manage the symptoms and prevention techniques. Dry mouth products
come in a variety of forms including, gum, mints, toothpaste, mouth rinse, lozenges,
lubricants, and sprays. Patients should be advised to avoid products containing alcohol;
as alcohol has a drying effect. It is vital that dental practitioners educate patients on their
increased risk of dental caries and oral infections. Patients suffering from xerostomia can
be placed on a prescription fluoride treatment or toothpaste. Additional fluoride will aid
in remineralization of the tooth structure. Because of the increased risk of caries, patients
need to be provided with nutritional counseling, regarding cariogenic food and
noncariogenic food. In an article in The Consultant Pharmacist it states that sipping
water throughout the day also may offer relief for affected patients. Ice chips can also
provide moisture and possibly alleviate symptoms.60 Dental practitioners play a large
role in managing xerostomia. They must provide patients with accurate information and
product recommendations.
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CHAPTER III
METHODOLOGIES
The purpose of this study was to examine New Mexico dental practitioners’
knowledge of the adverse oral effects of low-dose methotrexate, diltiazem, cyclosporine,
isotretinoin, and lisinopril. The study included an assessment of where this knowledge is
obtained.
This study examined New Mexico dental practitioners’ knowledge of adverse oral
effects of low-dose methotrexate, diltiazem, cyclosporine, iostretinoin, and lisinopril. An
informed consent and survey was sent to all licensed dentists and dental hygienists in
New Mexico; we will refer to these participants as “subjects”. The subjects’ contact
information was obtained from New Mexico Board of Dental Health Care; this
information was kept on file at The University of New Mexico’s Dental Hygiene
Division. Subjects in New Mexico were selected by a convenience census. Those who
were interested and qualified to participate in the adverse oral effects study were asked to
complete a survey. By returning the anonymous survey in the envelope provided subjects
agreed to participate in the study. Exclusion criteria were as follows: subjects who had
either a suspended or inactive license; those subjects not wishing to complete the survey
and therefore not providing informed consent; and subjects who were unable to
understand the survey.
Senior dental hygiene students at UNM were used as the control group. These
students have taken a general pharmacology course within the last year and provided a
comparison group. Senior dental hygiene students were presented information on
methotrexate, diltiazem, cyclosporine, and lisinopril (this drug classification is addressed,
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but not lisinopril specifically). Accutane (isotrenion) is not addressed in this course.
Throughout the students’ education, adverse oral reactions to pharmaceuticals are also
discussed in oral pathology, periodontology, and clinical courses. Exclusion criteria were
as follows: senior students who are not present the day the survey was distributed and
those not wishing to participate, therefore; not providing informed consent.
Sample Description
All subjects from New Mexico (2,148) received a copy of the survey and consent
letter in the mail. Both male and female subjects ranged in age, experience, number of
continuing education hours completed, and educational background. In addition to the
dental providers, senior dental hygiene students (23 students) at UNM participated in the
study. This allowed for internal control of the study when evaluating medications that
induce gingival hypertrophy.
Research Design
The research was designed as a descriptive survey study. The selection of
subjects was a process of convenience census; every dental provider in the state of New
Mexico was sent an informed consent letter and a survey in the mail. The questionnaire
was identified with a survey number and consisted of ten questions which included two
questions about each medication; one true/false and one multiple-choice question:
1. Diltiazem-induced gingival hypertrophy commonly appears on the attached
gingiva.
2. Diltiazem is used to treat which common medical condition?
3. Low-dose methotrexate can be used in the treatment of autoimmune diseases
such as, arthritis and psoriasis.
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4. Which are the MOST COMMON adverse oral side effects associated with
low-dose methotrexate.
5. Isotretinoin (Accutane) causes angular cheilitis in patients using this
medication.
6. Isotretinoin (Accutane) is used in the treatment of which condition?
7. Patients taking lisinopril do not report symptoms of xerostomia until saliva
production has been reduced by 100%.
8. Lisinopril-induced xerostomia increases patients’ risk of developing what oral
manifestation?
9. When a patient has cyclosporine-induced gingival hypertrophy, this
overgrowth is noted primarily in the posterior interdental papilla.
10. Which is a common pharmacological use of cyclosporine?
Demographic information was collected, which included: educational institution
attended, years in practice, continuing education hours completed, and the dental
providers’ credentials. The purpose of the anonymous survey was to compare knowledge
of the five medications being studied. In addition, results were compared between
demographic groups. These variations included years of experience, degree earned,
number of continuing education hours participated in each year, and type of dental
provider.
The same subjects participated throughout the study. Senior dental hygiene
students at UNM served as the control group during the investigation of Hypotheses 4
and 5. The control group’s responses were not computed for Hypotheses 1, 2, and 3
because it was assumed during the investigation that they would have been most familiar
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with gingival hypertrophy when compared to other adverse oral effects. The control
group completed the same survey as the subjects.
Data Analysis
After all the results from the study had been gathered, Minitab Release 14.20
(2005) statistical software was used to analyze the data. A descriptive analysis of all data
was conducted. For there to be a statistical significance, a P-value of < 0.05 was
required. While evaluating the data, a two-sample t-test was used to determine whether
two population means were equal, and a one-way ANOVA was used to compare the
means of two or more samples/groups. Since five individual hypotheses were examined
during this study, specific data analysis for each hypothesis will be discussed.
Two different data analyses were performed on the respondent sample in order to
summarize the collected data. First, each of the correct and incorrect number of
responses was tallied for each question. Secondly, responses to questions corresponding
to each medication (one true/false and one multiple choice question) were tallied. For
purposes of calculating the data, the answers were coded to express either a correct or
incorrect response. An incorrect response with coded with the number zero, one correct
response was coded with a number one, and two correct responses were coded with a
number two. This coding system does not specifically identify which of two responses
were answered incorrectly. For both, an analysis of the mean, standard error of the mean,
and standard deviation were calculated.
Hypothesis 1: Subjects’ knowledge regarding adverse oral effects of investigated
pharmaceuticals is greater as the educational levels increase.
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To test this hypothesis, the total number of correct responses was compared to the
highest degree earned. A one-way ANOVA was used to explore any significant
differences in knowledge based on degrees.

Hypothesis 2: The longer length of time that subjects have practiced, the less
knowledge subjects have regarding adverse oral effects of the investigated medications.
The total number of correct responses was compared to the number of years
practicing. The number of years practicing ranged from 0-30+ years. A one-way
ANOVA was used to explore any significant differences in knowledge based on years of
experience.

Hypothesis 3: Subjects who participate in at least twenty-six hours of continuing
education will have more knowledge in adverse oral effects of pharmaceuticals than
those who participate in fewer continuing education hours.
To test this hypothesis, the total number of correct responses for those subjects
participating in twenty-five hours or fewer of continuing education hours was tallied.
The same tally for subjects participating in at least twenty-six hours of continuing
education was completed. A one-way ANOVA was used to explore any significant
difference in knowledge based on continuing education.

Hypothesis 4: Subjects will be knowledgeable regarding adverse oral effects
associated with gingival hypertrophy, therefore; answering half of the related questions
correctly.
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The total number of incorrect and correct scores was tallied (using the coding
system previously mentioned) from questions one and nine. Descriptive statistics were
used to analyze the data for the testing of this hypothesis. The mean, standard error of
the mean, and standard deviation was calculated. The result of these calculations
provided an average score for subjects’ knowledge of gingival hypertrophy.

Hypothesis 5: Senior dental hygiene students at The University of New Mexico
will knowledgeable regarding medications that induce gingival hypertrophy, therefore;
answering half of the associated questions correctly.
To test this hypothesis, the total number of incorrect and correct responses was
tallied for questions one and nine (using the established coding system previously
discussed), and descriptive statistics were calculated. This hypothesis utilized the control
group and the sample group. A two-sample t-test was used to compare the distribution of
the mean, standard error of the mean, and standard deviation between the control and
sample groups.
Study Approval
The Human Research Review Committee (HRRC) at UNM approved this study.
The associated study number of HRRC# 08-443 can be referenced for this research study.
In addition, the letters of consent and participant surveys also had the approval of the
HRRC. In returning the completed survey, New Mexico dental providers and UNM
senior dental hygiene students provided an informed consent for this research.
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CHAPTER IV
RESULTS
A total of 2,148 surveys were mailed to subjects in New Mexico; this consisted of
1,083 dentists and 1,010 registered dental hygienists. Twenty-three senior dental hygiene
students at UNM also participated in this study as a control group. Two hundred and
eighty-four surveys were completed and returned by the requested date of November 10,
2008. Twenty-three completed surveys were returned after the deadline; these subjects’
responses were not included with the computations of the final data.
The survey used in this research classified dentists and registered dental
hygienists as “subjects.” Of the participants, 145 (51.1%) were dentists and 139 (48.9%)
were registered dental hygienists. Participants were asked to provide demographic
information including: with what type of dental practice they were associated, how many
years they have practiced, and the highest degree they have earned. This information
provided a comparison for the number of correct responses to the demographic
information.
The subjects in this survey are likely representative of practicing dental providers
in the state of New Mexico. Due to subjects’ ability to maintain an active license but live
in different states, there exists the possibility that a small number of other states may be
represented in this study.
The survey that subjects completed for this research study inquired about how
they obtain information regarding adverse oral effects of pharmaceuticals. Subjects were
asked to select which of the options applied to them. The options that participants could
select were websites, newspapers, journals, conferences, seminars, and other. Subjects
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reported that the use of journals was the primary source for information on adverse oral
effects of pharmaceuticals. Table 1 illustrates where subjects obtain information
regarding adverse oral effects.
Table 1. Demographic statistics for where information is obtained for adverse oral
effects of pharmaceuticals.
Where subjects obtain information on pharmaceuticals
Source

Number of Participants

Percentage

Websites

129

45.5%

Newspapers

35

12.3%

Journals

223

78.5%

Conferences

166

58.4%

Seminars

194

68.3%

Other

101

35.5%

Additional demographic information collected from respondents included the
number of years they have practiced, the highest degree they earned, the number of
continuing education hours in which they participate yearly, and where they obtain
information regarding adverse oral effects from pharmaceuticals. The tested hypotheses
in this study explore subjects’ knowledge of adverse oral effects based on the number of
years practicing, highest degree earned, and annual continuing education hours. These
results are discussed further with each associated hypothesis.
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Respondent sample data observations and descriptive statistics:
A response rate of 13.2% was found due to 284 of the 2,148 survey recipients
responding. In addition, 23 surveys were received after the stated deadline. This
increased the response rate to 14.4%; however, because this was a time sensitive
investigation, the responses from these 23 subjects were not calculated into the final data.
Of the student control group, 100% of the control group responded. Figure 1 illustrates
the percentage of dentists, dental hygienists, and students participating in the study.
Participants were asked to identify the type of dental practice with which they were
associated. It was found that 84.5% worked in general dentistry. The remaining dental
specialties had a significantly smaller percentage of representation in this study. These
percentages varied from 1.8% to 4.7%.

Figure 1. The number of participants from each demographic group.
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A descriptive summary of the data collected for each medication was calculated.
Each medication being researched had one true/false and one multiple-choice question
associated with it. The responses were coded with a zero, one, or two; zero if both
answers were incorrect or no answer was given, one if one answer was incorrect, and a
two if both answers were correct. Subjects’ knowledge regarding oral health
complications and medications were evaluated during this study. Diltiazem-induced
gingival hypertrophy commonly appears on the attached gingiva.
1. Diltiazem is used to treat which common medical condition?
2. Low-dose methotrexate can be used in the treatment of autoimmune diseases
such as, arthritis and psoriasis.
3. Which are the MOST COMMON adverse oral side effects associated with
low-dose methotrexate.
4. Isotretinoin (Accutane) causes angular cheilitis in patients using this
medication.
5. Isotretinoin (Accutane) is used in the treatment of which condition?
6. Patients taking lisinopril do not report symptoms of xerostomia until saliva
production has been reduced by 100%.
7. Lisinopril-induced xerostomia increases patients’ risk of developing what oral
manifestation?
8. When a patient has cyclosporine-induced gingival hypertrophy, this
overgrowth is noted primarily in the posterior interdental papilla.
9. Which is a common pharmacological use of cyclosporine?
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Figure 2 illustrates the subjects’ responses for each medication. In the diagram,
each medication has three corresponding sections demonstrating no correct answers, one
correct answer, or two correct answers, respectively. This analysis and coding system did
not identify which of the two questions were answered correctly.
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Figure 2. Percentages of responses for each medication investigated in this study.

Hypothesis 1: Subjects’ knowledge regarding adverse oral effects of investigated
pharmaceuticals is greater as educational levels increase.
A one-way ANOVA was used to appraise if there was a difference between
educational levels and knowledge of the five predetermined medications by comparing
the total number of correct responses to the degrees earned. The control group’s data was
not used in this analysis because their data was only relevant to hypotheses four and five.
A dot plot was generated to display the dispersion of the subjects’ correct responses. The
dot plot represented in Figure 3 displays the participants’ correct responses in correlation
to the highest degree earned. The majority of dental providers answered eight or fewer
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questions correctly. The dot plot departs slightly from normality with a slight skew to the
left; however, this is not severe enough to doubt the results of the ANOVA test. An
individual 95% confidence interval was calculated for the mean based on the pooled
standard deviation. The means of the levels of educational degrees are centered on 5.3
with a spread from one to ten. The ANOVA test (Table 2) yielded a P-value of 0.196,
which is greater than alpha; therefore, it is concluded that there was no significant
difference in knowledge of adverse oral effects based the highest degree earned, and
Hypothesis 1 was supported.
Table 2. One-way ANOVA hypothesis test results for total score earned versus degrees
One-way ANOVA for Hypothesis 1
Hypothesis 1:
Subjects knowledge regarding adverse oral effects of investigated pharmaceuticals is
greater as educational levels increase
Degree

Number of Subjects

Mean

Associates

52

4.885

Bachelors

70

5.486

DDS

131

5.374

Masters

24

5.417

PhD

4

7.500

P-Value

0.196
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Dotplot of Total_score vs Degree
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Each symbol represents up to 2 observations.

Figure 3. Total number of correct responses correlating to the highest degree earned.

Hypothesis 2: The longer length of time that subjects have practiced, the less
knowledge subjects have regarding adverse oral effects of the investigated medications
A one-way ANOVA was used to test this hypothesis by comparing the total
numbers of correct responses to the number of years the subject respondents have been
practicing. The control group’s data was not used in this analysis because their data was
useful for questions regarding gingival hypertrophy. On the survey, dental practitioners
were able to select from 0 years to more than 30 years practicing. As with the previous
hypothesis, an individual 95% confidence interval for the mean based on pooled standard
deviation was calculated; all means varied from 5.037-6.333 with a spread from zero to
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ten. The dot plot (Figure 4) is used to illustrate the distribution of data. A slight skew to
the left can be witnessed, but this is not severe enough to dispute the results of the
ANOVA hypothesis test. The one-way ANOVA test revealed a P-value of 0.661, which
is greater than set alpha (Table 3); therefore, there was no significant difference in
knowledge of adverse oral effects for the five investigated pharmaceuticals based on
years practicing.

Dotplot of Total_score vs Years
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Each symbol represents up to 2 observations.

Figure 4. Total number of responses correlating to the number of years practicing.
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Table 3. One-way ANOVA hypothesis test results for Hypothesis 2.
One-way ANOVA for Hypothesis 2
Hypothesis 2:
The longer length of time subjects have practiced the less knowledge they will have
regarding adverse oral effects of medications
Years practicing

Number of
Participants

Mean

0-2

9

6.333

3-9

36

5.583

10-15

28

5.393

16-20

27

5.037

21-30

95

5.358

30+

88

5.136

P-Value

0.661

A regression model was used to test an alternative to Hypothesis 2. This
regression model compared the number of years practicing with the total score. A large
P-value of 0.178 was obtained, which is consistent with the slope (-0.12335) and is not
different from zero. When responses were displayed graphically the data was
representative of a normal curve, but it is slightly skewed to the left with no difference
from zero. Thus, the number of years practicing does not predict the total score;
however, the negative slope of -0.12335 which is the means’s difference from zero,
suggests that the longer dental practitioners have been practicing, the less they know
about adverse oral effects of pharmaceuticals.
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Hypothesis 3: Subjects that participate in at least twenty-six hours of continuing
education will have more knowledge in adverse oral effects of pharmaceuticals than
those that participate in fewer continuing education hours.
A one-way ANOVA was used to explore any significant statistical difference in
dental providers’ knowledge based on the number of hours of continuing education. The
total number of correct responses for those subjects participating in twenty-five hours or
fewer of continuing education hours was tallied. The same was tallied for respondents
participating in at least twenty-six hours of continuing education. The control group’s
responses were not factored in for this analysis because their responses were used during
the investigation of drug-induced gingival hypertrophy. An individual 95% confidence
interval for mean based on the pooled standard deviation was calculated, with the two
means centered around 5.3 with a spread ranging from zero to ten. The one-way
ANOVA hypothesis test (Table 4) revealed a statistically significant difference (p =
0.022). Tukey’s HSD test was used to verify the results of the one-way ANOVA test,
thus confirming that there was a statistical difference between participants that
participated in twenty-five hours or fewer or continuing education and those that
participated in at least twenty-six hours of continuing education annually. Those
participating in at least twenty-six hours of continuing education scored an average of
0.629 higher than those who had fewer hours.
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Table 4. One-way ANOVA hypothesis test results for Hypothesis 3.
One-way ANOVA for Hypothesis 3
Hypothesis 3:
Subjects that participate in at least twenty-six hours of continuing education will have
more knowledge in adverse oral effects of pharmaceuticals than those that participate in
fewer continuing education hours.
Number of CE
hours

Number of
Participants

Mean

25 or fewer hours

176

5.084

26+ hours

115

5.713

P-Value

0.022

Hypothesis 4: Subjects will be knowledgeable regarding adverse oral effects
associated with gingival hypertrophy, therefore; answering half of the related questions
correctly.
Descriptive statistics (mean, standard error of the mean, and standard deviation)
were used to test this hypothesis. The total number of incorrect and correct answers for
questions one and nine were tallied. The answers were coded with a zero, one, or two,
corresponding to an incorrect answer/no response, one correct response, and two correct
responses, respectively. This coding system does not identify which of the two questions
subjects answered correctly. Table 5 illustrates the distribution of responses from the
subjects. A mean score of 0.6632 suggests that the subjects did not know about gingival
hypertrophy as it relates to diltiazem and cyclosporine in context of the two posed
questions.
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Table 5. Percentage of participants’ correct responses for Hypothesis 4.
Two Samples t-test
Hypothesis 4:
Subjects will be knowledgeable regarding adverse oral effects associated with gingival
hypertrophy, therefore; answering half of the related questions correctly.
Number of Correct
Responses

Number of Participants

Percentage

0

129

45.26

1

123

43.16

2

33

11.58

Average score = 0.6632
Standard Deviation = 0.6757

Upon closer examination of both questions one and nine on the survey, which
explore diltiazem and cyclosporines’ implication on the gingival tissue, a total of two
hundred seventy-five participants answered these questions. For both questions, the
participants could select one of three options: true, false, or I don’t know. In question
one, which states, “Diltiazem-induced gingival hypertrophy commonly appears on the
attached gingiva,” 45% of subjects answered true and 28% responded I don’t know.
However, only 27% answered false, which was the correct answer. In question nine,
“When a patient has cyclosporine-induced gingival hypertrophy, this overgrowth is noted
primarily in the posterior interdental papilla,” 10% answered true and 48% I don’t know.
These were both the incorrect choice. The correct response was false, which 42% of
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subjects correctly answered. This suggests that subjects performed worse than expected
even if they had randomly guessed the correct answer.
Hypothesis 5: Senior dental hygiene students at The University of New Mexico
will be knowledgeable regarding medications that induce gingival hypertrophy,
therefore; answering half of the associated questions correctly.
Descriptive statistics (mean, standard error of the mean, and standard deviation)
were used to test this hypothesis. The total number of incorrect and correct responses
were tallied for questions one and nine for the twenty-three student participants.
1. Diltiazem-induced gingival hypertrophy commonly appears on the attached
gingiva.
2. When a patient has cyclosporine-induced gingival hypertrophy, this overgrowth
is noted primarily in the posterior interdental papilla.
Both true/false questions answers were coded using the same system described in
Hypothesis 4: zero, one, and two. Table 6 demonstrates the percentage distribution of
responses from the control group for questions regarding gingival hypertrophy. The
mean score of 0.435 suggests that the control group did not have knowledge regarding
gingival hypertrophy. As with the subjects that participated in this study, data suggests
that the control group scored worse than expected even if they had randomly guessed the
correct answer.
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Table 6. Percentage of participants’ correct responses for Hypothesis 5.
Two Samples t-test
Hypothesis 5:
Senior dental hygiene students at The University of New Mexico will knowledgeable
regarding medications that induce gingival hypertrophy, therefore; answering half of the
associated questions correctly.
Number of Correct
Responses

Number of Participants

Percentage

0

15

65.22

1

6

26.09

2

2

8.70

Average score = 0.435
Standard Deviation = 0.662

A two-sample t-test was used to compare the scores of the control and sample
group. A 95% confidence interval was calculated with an upper limit of 0.0654 and a
lower limit of -0.526, which includes zero. The control group scored lower on these two
questions than the subjects with a mean difference of -0.230 (Table 7). However, this
difference was not statistically significant with a p-value of 0.196.

50

Table 7. Comparison of means between the subjects and the control groups scores.
Two Sample t-test
Comparison Of Results For Hypotheses 4 and 5:
Group

Number of Participants

Mean

Students (control)

23

0.435

Dental providers (sample)

284

0.665
Mean difference = -0.230
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CHAPTER V
DISCUSSION
To the investigators’ knowledge, this is the first study that has been conducted
regarding subjects knowledge on the five specific medications evaluated during this
investigation. Many times, patients do not report adverse oral effects to dental providers
because the effects are subtle or they are associated with other systemic or oral
conditions. Because of this, there is a minimal amount of research on pharmaceuticals’
adverse effects on the oral cavity.
All subjects held a current license and were selected for this study by means of a
convenience census. Subjects were sent a time sensitive, 10-question survey and letter of
consent in the mail. Two hundred eighty-four of the 2,148 survey recipients participated
in this investigation. Subjects in this study were either dentists or dental hygienists; of
the total number of participants 51% were dentists and 49% were dental hygienists. In
addition, 23 senior dental hygiene students at UNM were utilized as a control group for
questions on the survey pertaining to gingival hypertrophy. It was the assumption of this
investigative team that the control group would be most knowledgeable regarding this
particular adverse oral effect because of their student status. At UNM, students are
required to take a pharmacology course prior to their senior year.
Data analysis techniques during the collection of data included the use of
descriptive statistics, two sample t-tests, and one-way ANOVAs. An alpha level of 0.05
was established to determine whether or not a statistically significant difference could be
declared. From the data analysis performed, it was deemed that four of the five
hypotheses’ were not supported as a result of a high p-value. However, one hypothesis
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did demonstrate a statistically significant difference, therefore ruling in favor of the
alternative hypothesis.
Hypothesis 1: Subjects knowledge regarding adverse oral effects of investigated
pharmaceuticals is greater as educational level increases.
When analyzing this hypothesis, the assumption was that the education levels are
ranked in a hierarchy, beginning at an associates’ degree and increasing to a Ph.D. Table
3 illustrates that out of the 284 providers, four participants responded that they had
obtained a Ph.D. (three DDS and one RDH); these responses did not alter the results for
this hypothesis. Subjects’ level of knowledge regarding adverse oral effects does not
increase with an increase in the levels of education. The associated dot plot (Figure 3)
clearly illustrates that subjects’ responses are reasonably evenly distributed amongst the
various educational levels. The majority of subjects (excluding subjects with a Ph.D.)
answered eight or fewer of the survey questions correctly; these observations are
confirmed by a pooled standard deviation of 2.264. Thus, the shape of the bell curve is
much wider than it would be had the number of correct responses been densely populated
around higher levels of education. Results for this hypothesis suggest that dental
providers do not obtain more knowledge regarding adverse oral effects of
pharmaceuticals as they continue to move up the educational ladder. Instead, results
simply suggest that oral effects are addressed during one’s initial education, unlike the
preliminary thought that the more education one has, the more educators address adverse
oral effects in educational institutions.
Future studies could compare dentists and dental hygienists knowledge of adverse
oral effects. Unfortunately, this hypothesis was not examined during this investigation.
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Research results also suggest that future studies could include an investigation of both
dental and dental hygiene educational programs. Focusing on the timeframe and courses
during which one’s education of adverse oral effects is addressed could provide insight to
areas where more education is needed. An investigation into the effectiveness of a
dental-specific pharmacology course could provide additional useful information. In the
future, this study could be expanded to compare the effectiveness of specific dental
pharmacology courses versus a biomedical pharmacology course.
Hypothesis 2: The longer length of time that subjects have practiced, the less
knowledge subjects have regarding adverse oral effects of the investigated medications
It was the assumption of this hypothesis that knowledge of adverse oral effects is
associated with experience. A p-value larger than alpha was obtained, indicating that
there was no significant difference in knowledge of the predetermined medications and
oral health implications based on years practicing. An alternative regression model was
analyzed to compare the total score versus the number of years practicing. Again, the
large p-value continued to demonstrate that there was no significant difference in
knowledge of the five investigated pharmaceuticals’ oral effects based on years. A slight
variation to the left in the normal bell curve, with a slope of -0.12335, indicates that the
longer the subjects have been practicing, the less they know about adverse oral effects of
the five named pharmaceuticals. It should be mentioned that this was not a statistically
significant difference, but it suggests the need for future studies.
An investigation of dental providers’ knowledge and use of other key factors
pertaining to dentistry could be investigated; including the adverse oral effects of
pharmaceuticals, instrumentation techniques, product recommendations, integration of
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advanced technology, and the implementation of evidence-based dentistry. These results
could indicate that the longer subjects practice, the less they keep up with current
research, technology, or procedures. It may be assumed from the compiled data that
patients may not be receiving the most current information, thus potentially
compromising the quality of patient education. An evaluation of technique, procedures,
and research that are provided to patients from providers who have been practicing
dentistry for longer periods may beneficial to both patients and providers. This could
provide insight on how to motivate and update those practitioners who have been
practicing for extended lengths of time. The government mandating the use of electronic
medical and dental records may initiate a renewed sense of exploration and technology in
the field of dentistry. It is the expectation of patients that they receive current quality and
evidenced-based dental care.
Hypothesis 3: Subjects that participate in at least twenty-six hours of continuing
education will have more knowledge in adverse oral effects of pharmaceuticals than
those that participate in fewer continuing education hours.
Through the use of a one-way ANOVA, a small P-value of 0.022 was obtained.
This was indicative of a statistically significant difference in knowledge of the specially
named medications and their associated oral manifestations based on the number of
continuing education hour’s subjects participated in yearly. The difference between
subjects participating in at least twenty-six hours versus twenty-five or fewer hours was
0.629. The specific reason for this difference is not known.
Assumptions can be made to account for this difference regarding those subjects
that participate in at least twenty-six hours of continuing education per year. It could be
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that these subjects enrolled in continuing education courses that addressed
pharmaceuticals and their implications on the oral cavity. Even if these courses do not
address adverse oral effects specifically, it is plausible that this topic would be briefly
addressed in pharmacology seminars. The majority of states require that both dentists
and dental hygienists participate in continuing education in order to maintain an active
license. The state of New Mexico requires that dentists and dental hygienists complete a
minimum of sixty (DDS) and forty-five hours (RDH) per triennial renewal cycle.61 New
Mexico mandates that a specific number of courses be taken at seminars/conventions,
whereas other hours can be obtained from journals and on-line coursework. This factor
could account for the significant difference between twenty-five or fewer and at least
twenty-six continuing education hours participated in annually.
This difference in scores can also be associated with Hypothesis 2. It is plausible
that the same subjects who have been practicing longer and performed slightly worse on
the survey participated in fewer continuing educations hours. This assumption provides
opportunities for further studies; investigation into the correlation between the length of
time practicing and the number of continuing education hours would be useful in
accounting for the difference discovered in this study. Perhaps an evaluation into the
effectiveness of continuing education from journals, periodicals, and on-line courses
would be useful. The results from an investigation could provide insight and change to
the current regulations set forth by the New Mexico Board of Dental Health Care.
Hypothesis 4: Subjects will be knowledgeable regarding adverse oral effects
associated with gingival hypertrophy, therefore; answering half of the related questions
correctly.
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Two questions in this investigation addressed medications that induce gingival
hypertrophy, both of which were true/false questions:
1. Diltiazem-induced gingival hypertrophy commonly appears on the attached
gingiva.
2. When a patient has cyclosporine-induced gingival hypertrophy, this overgrowth
is noted primarily in the posterior interdental papilla.
In the consent letter, subjects were instructed that they were not required to answer a
question if they did not understand it or did not feel comfortable. Of the 284 surveys
returned, 275 subjects answered both questions 1 and 9. In question number one, the
survey inquired as to if diltiazem-induced gingival hypertrophy commonly appears on the
attached gingiva. Seventy-three percent of subjects either responded true or I don’t
know; the correct response was false. Statistically, this indicated that this question was
exceptionally difficult for subjects. For question nine, 58.1% of subjects answered it
incorrectly, while 41.8% answered it correctly. This question presented less difficulty for
the subjects than question one.
An average score of 0.6632 does not suggest that subjects in New Mexico knew
about gingival hypertrophy in the context of the two posed questions. In fact, subjects
scored worse on these two questions statistically than they would have if they had simply
guessed. If subjects had guessed at random, 25% would have answered both questions
incorrectly, 50% answered one question correctly, and 25% answered both questions
correctly. Gingival hypertrophy is commonly taught in educational settings, as this can
complicate dental treatment, oral health, and have an aesthetic impact on the patient. It is
important that dental providers be familiar with the characteristic appearances and
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location of gingival hypertrophy. This data may suggest that more education is needed in
this area to assist in educating dental providers of this commonly witnessed adverse oral
effect. This education can be in a variety of forms including articles, research, seminars,
and information from pharmaceutical companies. It should be acknowledged that the
sole responsibility of providing and obtaining information regarding gingival hypertrophy
does not fall primarily on dental providers. Research can be done by pharmaceutical
companies to assist in determining the number of patients on drug therapies that induce
gingival hypertrophy and how frequently it occurs. Pharmaceutical companies also have
the opportunity to educate dental providers on the likelihood of this condition occurring.
Dental providers should take the initiative to investigate medications that the patient is
taking. This will not only educate providers on adverse oral effects, but also allow them
to provide the patient with the appropriate education and information regarding any
adverse oral effects they may be experiencing or could experience.
Hypothesis 5: Senior dental hygiene students at The University of New Mexico
will be knowledgeable regarding medications that induce gingival hypertrophy,
therefore; answering half of the associated questions correctly.
Similar to the fourth hypothesis, questions one and nine were used to investigate
this hypothesis. The percentage of the control group that responded incorrectly with
answering either true or I don’t know to question one was 78.2%, whereas the correct
response was false. In questions nine, 73.9% of the control responded true or I don’t
know; the correct answer was false, with 26.1% answering correctly. The control groups
average score is 0.435, which suggests that they did not have knowledge of gingival
hypertrophy in the context of the posed questions. Similarly to the subjects, the control
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group performed worse than expected had they simply guessed the correct response at
random. Students scored lower than the dental providers did, but not significantly worse.
It was the expectation during this study that the control group would score higher
on the questions pertaining to gingival hypertrophy than the subjects. The control group
would have been educated on this adverse oral effect throughout their course work at
UNM. Currently, dental hygiene students take a general pharmacology course that
includes other branches of healthcare. An evaluation into the effectiveness of a
pharmacology course specifically designed for dental professionals may be of interest to
UNM and other educational institutions. These results yield insight to areas of further
study regarding adverse oral effects. Implementing a discussion regarding gingival
hypertrophy into other dental hygiene courses at UNM may assist in increasing students’
knowledge of this adverse oral complication as it relates to diltiazem and cyclosporine.
In conclusion, statistical data suggests that further studies are needed to evaluate
the occurrence of these adverse oral effects, in addition to assess the deficiencies in
dental providers’ knowledge of adverse oral effects. This investigation offers insight to
areas where there is a lack of information for both students and dental providers. Future
studies can be implemented to evaluate the educational process for both dental and dental
hygiene students in regards to pharmacology and adverse oral effects. However, to
adequately educate students, a key factor will be further investigation into the occurrence
rate of adverse effects and which medications are more prevalent for causing an adverse
response. As dental providers, patients seek medical advice and guidance; the lack of
information and knowledge on adverse oral effects may be a disservice to the patient.
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This study is indicative of what is needed and of what is yet to come in the investigation
of adverse oral effects of pharmaceuticals.

60

APPENDIX 1: DATA ANALYSIS
Respondent data analysis:
Tally for Discrete Variables: s01
s01
0
1
N=

Count
210
74
284

Percent
73.94
26.06

Tally for Discrete Variables: s02
s02
0
1
N=

Count
98
186
284

Percent
34.51
65.49

Tally for Discrete Variables: s03
s03
0
1
N=

Count
81
203
284

Percent
28.52
71.48

Tally for Discrete Variables: s04
s04
0
1
N=

Count
180
104
284

Percent
63.38
36.62

Tally for Discrete Variables: s05
s05
0
1
N=

Count
144
140
284

Percent
50.70
49.30

Tally for Discrete Variables: s06
s06
0
1
N=

Count
43
241
284

Percent
15.14
84.86

Tally for Discrete Variables: s07
s07
0
1
N=

Count
120
164
284

Percent
42.25
57.75

Tally for Discrete Variables: s08
s08
0
1
N=

Count
208
76
284

Percent
73.24
26.76

Tally for Discrete Variables: s09
s09
0
1
N=

Count
169
115
284

Percent
59.51
40.49
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Tally for Discrete Variables: s10
s10
0
1
N=

Count
81
203
284

Percent
28.52
71.48

Tally for Discrete Variables: d1_Diltiazem
d1_Diltiazem
0
1
2
N=

Count
76
156
52
284

Percent
26.76
54.93
18.31

Tally for Discrete Variables: d2_Methotrexate
d2_Methotrexate
0
1
2
N=

Count
75
111
98
284

Percent
26.41
39.08
34.51

Tally for Discrete Variables: d3_Isotretinoin
d3_Isotretinoin
0
1
2
N=

Count
33
121
130
284

Percent
11.62
42.61
45.77

Tally for Discrete Variables: d4_Lisinopril
d4_Lisinopril
0
1
2
N=

Count
97
134
53
284

Percent
34.15
47.18
18.66

Tally for Discrete Variables: d5_Cyclosporine
d5_Cyclosporine
0
1
2
N=

Count
68
114
102
284

Percent
23.94
40.14
35.92

Descriptive Statistics: d1_Diltiazem, d2_Methotrexate, d3_Isotretinoin,
d4_Lisinopril, d5_Cyclosporine
Variable
d1_Diltiazem
d2_Methotrexate
d3_Isotretinoin
d4_Lisinopril
d5_Cyclosporine

Mean
0.9155
1.0810
1.3415
0.8451
1.1197

SE Mean
0.0396
0.0461
0.0402
0.0422
0.0454

StDev
0.6672
0.7776
0.6774
0.7113
0.7657
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Tally for Discrete Variables: Total_score
Total_score
0
1
2
3
4
5
6
7
8
9
10
N=

Count
8
12
18
25
36
43
40
51
34
15
2
284

Percent
2.82
4.23
6.34
8.80
12.68
15.14
14.08
17.96
11.97
5.28
0.70

Descriptive Statistics: Total_score
Variable
Total_score

Mean
5.303

SE Mean
0.137

StDev
2.305

Hypotheses:
1. The higher levels of education mean an increased level of knowledge regarding
adverse oral effects of pharmaceuticals.
Results: There are no significant differences in knowledge based on degree.
One-way ANOVA: Total_score versus Degree
Source
Degree
Error
Total

DF
4
276
280

S = 2.264

Level
Associates
Bachelors
DDS
Masters
PhD

SS
31.22
1414.30
1445.52

MS
7.80
5.12

R-Sq = 2.16%

N
52
70
131
24
4

Mean
4.885
5.486
5.374
5.417
7.500

F
1.52

P
0.196

R-Sq(adj) = 0.74%

StDev
1.947
2.276
2.325
2.636
0.577

Individual 95% CIs For Mean Based on
Pooled StDev
--+---------+---------+---------+------(----*---)
(---*--)
(--*-)
(-----*-----)
(--------------*--------------)
--+---------+---------+---------+------4.5
6.0
7.5
9.0

Pooled StDev = 2.264
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Individual Value Plot of Total_score vs Degree
10

Total_score

8

6

4

2

0
Associates

Bachelors

DDS
Degree

64

Masters

PhD

2. The longer period of time that dental providers have practicing, the less
knowledge they will have regarding adverse oral effects of medications.

Dotplot of Total_score vs Years
00-02 years
03-09 years
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Each symbol represents up to 2 observations.

Results: There are no significant differences in knowledge based on years.
One-way ANOVA: Total_score versus Years
Source
Years
Error
Total

DF
5
277
282

S = 2.295

Level
00-02 years
03-09 years
10-15 years
16-20 years
21-30 years
30+ years

SS
17.15
1458.59
1475.74

MS
3.43
5.27

R-Sq = 1.16%

N
9
36
28
27
95
88

Mean
6.333
5.583
5.393
5.037
5.358
5.136

F
0.65

P
0.661

R-Sq(adj) = 0.00%

StDev
1.500
2.430
2.061
2.192
2.226
2.464

Individual 95% CIs For Mean Based on
Pooled StDev
--------+---------+---------+---------+(--------------*--------------)
(-------*------)
(--------*-------)
(-------*--------)
(----*---)
(---*----)
--------+---------+---------+---------+5.0
6.0
7.0
8.0

Pooled StDev = 2.295
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Regression Analysis: Total_score versus C
The regression equation is
Total_score = 5.88 - 0.123 C
Predictor
Constant
C

Coef
5.8777
-0.12335

S = 2.28425

SE Coef
0.4332
0.09124

R-Sq = 0.6%

T
13.57
-1.35

P
0.000
0.178

R-Sq(adj) = 0.3%

3. Dental providers that participate in at least twenty-six hours of continuing
education will have more knowledge in adverse oral effects of pharmaceuticals than
those that participate in fewer continuing education hours.

H5_26hours

Dotplot of Total_score vs H5_26hours

25- hours

26+ hours

0

2

4
6
Total_score

8

10

Each symbol represents up to 2 observations.

Results: There is a significant difference in knowledge based on continuing education
hours 26+ versus 25-, scoring an average of 0.629 higher.

66

One-way ANOVA: Total_score versus H5_26hours
Source
H5_26hours
Error
Total

DF
1
280
281

S = 2.252

R-Sq = 1.86%

Level
25- hours
26+ hours

N
167
115

SS
26.96
1420.36
1447.32

Mean
5.084
5.713

MS
26.96
5.07

F
5.32

P
0.022

R-Sq(adj) = 1.51%

StDev
2.216
2.305

Individual 95% CIs For Mean Based on
Pooled StDev
-----+---------+---------+---------+---(---------*---------)
(-----------*-----------)
-----+---------+---------+---------+---4.90
5.25
5.60
5.95

Pooled StDev = 2.252

4. Dental providers will be able to answer half the questions with adverse oral
effects associated with gingival hypertrophy.
Results: Average score is 0.6632, which does not suggest that they know about Gingival
Hypertrophy in the context of the two posed questions. In fact, they did worse than
expected if they simply guessed at random (which would have 0.25 0’s, 0.5 1’s, and 0.25
2’s)!
Tally for Discrete Variables: H4_1_9_GingivalHypertrophy
H4_1_9_GingivalHypertrophy
0
1
2
N=

Count
129
123
33
285

Percent
45.26
43.16
11.58

Descriptive Statistics: H4_1_9_GingivalHypertrophy
Variable
H4_1_9_GingivalH

N*
0

Mean
0.6632

SE Mean
0.0400

StDev
0.6757

67

Minimum
0.0000

Q1
0.0000

Median
1.0000

Q3
1.0000

Maximum
2.0000

Chart of H4_1_9_GingivalHypertrophy
140
120

Count

100
80
60
40
20
0

0

1
H4_1_9_GingivalHypertrophy

2

5. Senior dental hygiene students at The University of New Mexico will be able to
answer half the questions regarding medications that induce gingival hypertrophy.
Results: Average score is 0.435, which does not suggest that they know about Gingival
Hypertrophy in the context of the two posed questions. In fact, they did worse than
expected if they simply guessed at random (which would have 0.25 0’s, 0.5 1’s, and 0.25
2’s), and even worse than the practitioners (but not significantly worse)!
Tally for Discrete Variables: H4_1_9_GingivalHypertrophy
H4_1_9_GingivalHypertrophy
0
1
2
N=

Count
15
6
2
23

Percent
65.22
26.09
8.70

Descriptive Statistics: H4_1_9_GingivalHypertrophy
Variable
H4_1_9_GingivalH

N*
0

Mean
0.435

SE Mean
0.138

StDev
0.662

Minimum
0.000
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Q1
0.000

Median
0.000

Q3
1.000

Maximum
2.000

Chart of H4_1_9_GingivalHypertrophy
16
14
12

Count

10
8
6
4
2
0

0

1
H4_1_9_GingivalHypertrophy

2

Two-Sample T-Test and CI: H4_1_9_GingivalHypertrophy, Group
Two-sample T for H4_1_9_GingivalHypertrophy
Group
Control
Sample

N
23
284

Mean
0.435
0.665

StDev
0.662
0.676

SE Mean
0.14
0.040

Difference = mu (Control) - mu (Sample)
Estimate for difference: -0.230710
95% CI for difference: (-0.526906, 0.065486)
T-Test of difference = 0 (vs not =): T-Value = -1.60
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P-Value = 0.121

DF = 25

APPENDIX 2: PARTICPANT SURVEY
Demographic Information:

Survey #:

What type of dental provider are you?
☐1 Dentist
☐2 Registered Dental Hygienist
What type of dental practice are you associated with?
☐1
☐2
☐3
☐4
☐5
☐6

General
Orthodontic
Oral Surgery
Pediatric
Endodontic
Periodontal

How many years have you been practicing?
☐1
☐2
☐3
☐4
☐5
☐6

0-2 years
3-9 years
10-15 years
16-20 years
21-30 years
30+ years

What is the highest degree earned?
☐1
☐2
☐3
☐4
☐5

Associates
Bachelors
DDS
Masters
Ph.D.

How many hours of continuing education do you participate in each year?
☐1
☐2
☐3
☐4

5-10 hours
11-15 hours
16-20 hours
21-25 hours
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☐5 26-30 hours
☐6 31+ hours
Where have you obtained information on adverse oral effects of pharmaceuticals that
patients may present with on their medical histories? (Circle all that apply)
☐1
☐2
☐3
☐4
☐5
☐6

Websites
Newspaper
Journals
Conferences
Seminars
Other __________

Adverse oral effects questionnaire: Please check the BEST answer.
1. Diltiazem-induced gingival hypertrophy commonly appears on the attached
gingiva.
☐1 True

☐2 False ***

☐3 I do not know

2. Diltiazem is used to treat which common medical condition?
☐1
☐2
☐3
☐4
☐5

Hypertension ***
Pulmonary embolism
Cardiac arrest
Bronchitis
I do not know

3. Low-dose methotrexate can be used in the treatment of autoimmune diseases such
as, arthritis and psoriasis.
☐1 True ***

☐2 False

☐3 I do not know

4. Which are the MOST COMMON adverse oral side effects associated with lowdose methotrexate.
☐1
☐2
☐3
☐4
☐5

Mucositis and oral ulcerations ***
Candidiasis and leukoplakia
Xerostomia and mucositis
Candidiasis and xerostomia
I do not know
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5.

Isotretinoin (Accutane) causes angular cheilitis in patients using this medication.
☐1 True ***

6.

☐2 False

☐3 I do not know

Isotretinoin (Accutane) is used in the treatment of which condition?
☐1
☐2
☐3
☐4
☐5

Psoriasis
Nodular acne ***
Sjrogen’s Syndrome
Migraine headaches
I do not know

7. Patients taking lisinopril do not report symptoms of xerostomia until saliva
production has been reduced by 100%.
☐1 True

☐2 False ***

☐3 I do not know

8. Lisinopril-induced xerostomia increases patients’ risk of developing what oral
manifestation?
☐1
☐2
☐3
☐4
☐5

Mucositis
Leukoedma
Candida albicans ***
Oral Ulceration
I do not know

9. When a patient has cyclosporine-induced gingival hypertrophy, this overgrowth is
noted primarily in the posterior interdental papilla.
☐1 True

☐2 False ***

☐3 I do not know

10. Which is a common pharmacological use of cyclosporine?
☐1
☐2
☐3
☐4
☐5

Hypertension
Cancer
Osteoporosis
Organ transplants ***
I do not know
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